top of page
  • phoebegullingsrud6

Exciting Opportunities in Kidney Research at ANC

ANC’s Clinical Trial Research

Here at ANC, we are thrilled to announce our participation in global clinical trials focused on developing new treatments for people with kidney disease. We are partnering with Davita Clinical Research to bring opportunities for our patients to have access to developing, cutting-edge treatments early on and we are excited to share this opportunity with you and anyone affected by kidney disease. 

Historically, participation in impactful research was often limited to very large practices and well-funded institutions far away from the Twin Cities. Now, as interest grows and more resources become available for studies in kidney disease, ANC and our partners at Intermed Consultants bring opportunities to our patients close to home. 

Key Studies at ANC and Intermed Consultants 

(1) Hyperparathyroidism in Dialysis Patients

One study participating in focuses on hyperparathyroidism in dialysis patients. Hyperparathyroidism is a complication in dialysis patients where over-activity of the parathyroid glands leads to bone disease. This trial takes place in our dialysis units and aims to improve calcium-phosphate balance in the body and prevent common dialysis complications. 

(2) Therapies for Specific Glomerular Diseases

We are recruiting for several studies of glomerular diseases which cause inflammation in kidney filters and can lead to kidney failure. In the past, we did not have good treatments for some of these diseases but now there’s been a lot of research, and promising new treatments have been developed. If you or someone you know has IgA Nephropathy, Focal Sclerosis, or Membranous Nephropathy, you may be eligible for a new drug trial. 

(3) Genetic Chronic Kidney Disease (CKD)

We are recruiting for a new study for patients with a genetic abnormality that raises the risk of severe kidney disease. Though 10% of the U.S. population is African American, they make up nearly 30% of dialysis patients. Abnormalities in the APOL1 gene are thought to be common in these individuals and explain much of the high incidence of severe kidney disease in African Americans.  There is an open study testing a new drug in patients with this genetic marker. If you are interested, screening for this gene is offered at no cost. For individuals with this genetic marker, there is a new treatment being tested to prevent kidney damage in patients with abnormal APOL1 variants. 

Getting Involved

If you or someone you know is interested in more information on time commitment, trial protocols, and compensation or participating in a clinical trial, call us.  

101 views0 comments

Recent Posts

See All


bottom of page